Pimovanserin Tartrate API

Name	Pimovanserin tartrate
Chinese name	酒石酸匹莫范色林
Cas Number	1080491-31-1
Source	India
Qualifications	USDMF/-/-/-/-

Pimovanserin tartrate was granted breakthrough treatment status by the FDA on February 9, 2014, and was approved by the FDA on April 29, 2016 for the treatment of Parkinson’s fantasy and delusion. It is currently the first and only approved use Drugs to treat Parkinson's mental illness. Pimovanserin tartrate is a selective serotonin inverse agonist, which not only preferentially targets 5-HT2A receptors, but also avoids the activation of dopamine receptors and other receptors that most schizophrenia drugs have Adverse reactions. Pimovanserin tartrate has high targeting and specificity for the reverse and antagonism of 5-HT2A receptors, and the selectivity is 40 times that of 5-HT2C receptors and dopamine receptors. The curative effect is good, the specificity is good, the deterioration of muscle movement is avoided, and the side effects are few. Pimovanserin tartrate's sales in 2017 reached 125 million US dollars.

Hot Tags: pimovanserin tartrate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Canagliflozin API, Clofarabine API, Pregabalin API, Pabxilib API, Solinasine Succinate API, Pleasant API

• Previous: Goserelin API
• Next: Levalbuterol Hydrochloride API